Radiation Therapy In Combination With Durvalumab For People With Pancreatic Cancer

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2017-08-07	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2024-10-04
First Submitted that Met QC Criteria 2017-08-07	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2024-10-08
First Posted (ACTUAL) 2017-08-10	Results First Posted N/A	Last Verified 2024-10

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Durvalumab + SABR Durvalumab + Stereotactic Ablative Body Radiotherapy	DRUG: Durvalumab Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously ( RADIATION: Stereotactic Ablative Body Radiotherapy (SABR) SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Durvalumab + SABR

Durvalumab + Stereotactic Ablative Body Radiotherapy

DRUG: Durvalumab

Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (

RADIATION: Stereotactic Ablative Body Radiotherapy (SABR)

SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.

Primary Outcome Measures	Measure Description	Time Frame
Number of participants with dose limiting toxicities in the first 10 weeks of treatment		10 weeks
Progression Free Survival	Duration of time from diagnosis to time of progression	12 months
Proportion of participants who have resectable disease	Based on overall downstaging of disease post-treatment	24 weeks
Progression Free Survival (Phase II)	From study enrollment to time of progression	6 months

Secondary Outcome Measures	Measure Description	Time Frame
Mean change in levels of inflammatory cytokines from baseline	As measured from cytokine analysis from serum	10 weeks
Mean change in levels of immune cells from baseline	As determined from flow cytometry from biopsies and blood	10 weeks
Mean change in protein levels from baseline	As determined from quantitative immunohistochemistry on biopsy samples	10 weeks
Mean change in microbiome from baseline	As determined from analysis of stool samples	10 weeks

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Patients with histopathologic or cytologic diagnosis of adenocarcinoma of the pancreas (PDAC), or suspicious for malignancy per pathology, which is deemed BR or LA PDAC per NCCN guidelines or following evaluation by a Multidisciplinary group of physicians.
Patients must have received FOLFIRINOX for 3-6 months prior to enrollment with at least stable disease by restaging imaging.

Age ≥ 18 years
Body weight >30kg
ECOG 0-2
Patients must have normal organ and marrow function as defined below:

Absolute Neutrophil Count (ANC) ≥1.0 K/mcL
Platelets ≥75 K/mcL
Hemoglobin ≥ 9 g/dL
Total bilirubin ≤ 1.5 X upper limit of normal (ULN)
AST(SGOT) and ALT(SGPT) ≤ 2.5 X ULN
Creatinine OR creatinine clearance ≤ 1.5 times the upper limit of normal OR > 40 mL/min for patients with creatinine levels above normal.

Negative pregnancy test in women of childbearing potential (WOCBP) within 30 days of durvalumab administration or evidence of post-menopausal status. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
Non-sterilized male participants who are sexually active with a female partner of childbearing potential must be willing to use a highly effective method of contraception from Day 1 through 90 days after receipt of the final dose of investigational product(s). Not engaging in sexual activity for the total duration of the study and the drug washout period is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male participants must be willing to refrain from sperm donation throughout these periods.
Ability to understand and the willingness to sign an informed consent document.
Willingness and ability to comply with the protocol including study treatment, scheduled assessments and follow-up.

History of another primary malignancy except for:

Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
Patients who have had prior anti-cancer treatment or are currently receiving anti-cancer treatment for their disease other than chemotherapy as stipulated by protocol.
Women who are breastfeeding.
Any clinically significant, unresolved toxicity >CTCAE grade 2 from previous anti-cancer therapy with the exception of alopecia, vitiligo and laboratory values defined in the inclusion criteria.
Patients with Grade ≥ 2 neuropathy will be included at the investigator's discretion
Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included at the nvestigator's discretion
Patients who are currently receiving any other investigational agents for therapeutic treatment of their primary cancer.
Any previous treatment with a PD1 or PD-L1 inhibitor, including Durvalumab or other immunotherapy.
Known metastatic disease.
Major surgical procedures based on clinical judgement of the investigator within 30 days prior to the first dose of study drug. Patients may undergo staging laparoscopy, PTC placement, ERCP, etc. at any time which should not interfere with study treatment.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Patients who are receiving radiation treatment outside of the enrolling centers.
Patients with frank transmural macroscopic invasion of duodenum by tumor as determined by treating investigator.
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis, Crohn's disease], diverticulitis with the exception of diverticulosis, celiac disease, irritable bowel syndrome, or other serious gastrointestinal chronic conditions associated with diarrhea); systemic lupus erythematosus; Wegener syndrome (granulomatosis with polyangiitis; Graves' disease; rheumatoid arthritis, hypophysitis, uveitis, etc) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion: Patients with vitiligo or alopecia. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement, or psoriasis not requiring systemic treatment
Current or prior use of immunosuppressive medication within 28 days before treatment, except with chemotherapy.
History of organ transplant that requires use of immunosuppressive agents.
History of active primary immunodeficiency.
Receipt of live attenuated vaccination within 30 days prior to receiving durvalumab.
Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings and TB testing in line with local practices), active bleeding diatheses, hepatitis B (known positive HBV surface antigen result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).
Patient with known active Hepatitis (i.e. Hepatitis B or C).

Active hepatitis B virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg and PCR negative) are eligible.
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Patients with macroscopic invasion of the bowel or stomach submucosa by primary pancreatic tumor as determined by PI.

Collaborators and Investigators

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Learn

Resources

PatientS

Caregivers

Clinical Trial Record